Form 4: Tandem Diabetes Care CEO John F. Sheridan Reports Stock Transactions
SEC Form 4
John F. Sheridan, CEO of Tandem Diabetes Care, reports the vesting and tax withholding of restricted stock units, resulting in adjustments to his holdings of common stock.
Summary
- On August 15, 2024, John F. Sheridan, the President & CEO of Tandem Diabetes Care Inc. (TNDM), engaged in transactions involving common stock and restricted stock units (RSUs).
- These transactions included the vesting of RSUs and the subsequent withholding of shares to cover tax obligations.
- Specifically, 793, 2,236, and 5,472 RSUs vested, converting into common stock.
- To satisfy tax withholding requirements, 402, 1,134, and 2,774 shares were withheld by the company at a price of $43.82 per share.
- Following these transactions, Sheridan directly owns 49,766 shares of Tandem Diabetes Care Inc.
- The RSUs were granted under the company's 2013 and 2023 Stock Incentive Plans and vest in installments.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing. It doesn't inherently indicate positive or negative sentiment, but rather reports factual transactions.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the CEO's holdings in Tandem Diabetes Care.
Comparison to Industry Standards
- Executive compensation packages including stock options and restricted stock units are standard practice among publicly traded companies, particularly in the technology and healthcare sectors.
- Companies like Insulet and Dexcom also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules and tax withholding practices described in the filing are typical for RSU grants.
Stakeholder Impact
- The transactions reported may have a minor impact on shareholders due to the change in the CEO's stock ownership.
- Employees holding similar RSUs may be interested in the vesting schedule and tax implications.
Key Dates
| Date | Description |
|---|---|
| 05/18/2021 | Date of RSU award pursuant to the 2013 Stock Incentive Plan. |
| 05/15/2022 | First vesting date (25%) for RSUs awarded on May 18, 2021. |
| 05/25/2022 | Date of RSU award pursuant to the 2013 Stock Incentive Plan, as amended. |
| 05/15/2023 | First vesting date (33%) for RSUs awarded on May 25, 2022. |
| 05/25/2023 | Date of RSU award pursuant to the 2023 Long-Term Incentive Plan, as amended. |
| 05/15/2024 | First vesting date (33%) for RSUs awarded on May 25, 2023. |
| 08/15/2024 | Date of reported transactions: RSU vesting and tax withholding. |
| 08/19/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.